cancer

Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption

  • by

What You Should Know: – Philips and Ibex Medical Analytics announced a strategic partnership to globally commercialize clinically proven, AI-powered digital pathology solutions. The collaboration further cements Philips’ commitment to integrated diagnostics providing a clear path to precision diagnosis. – The trend towards centralized pathology labs, the… Read More »Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption

Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

  • by

What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced… Read More »Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

  • by

Shots: The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix Mabxience’s MB02 to be marketed as… Read More »mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model

  • by

What You Should Know: – Omega Healthcare, a provider of outsourced revenue cycle management and other healthcare support services, today announced the acquisition of himagine Solutions, a St. Louis based provider of medical coding and registry services. The transaction expands the service capabilities and geographical footprint of both companies, enhancing… Read More »Omega Healthcare Acquires himagine Solutions to Expand Global Delivery Model

How do you get all the data quality benefits of eCOA in less time and at lower cost?

  • by

Upcoming oncology trial? Which oncology eCOA Package offers the best ability to capture reliable endpoint evidence to increase speed, reduce cost, and ensure consistency across sites and geographies in less time? Find out. Consider these data points: 334 studies 158,000+ patients 67 countries 44,000+ sites… Read More »How do you get all the data quality benefits of eCOA in less time and at lower cost?

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

  • by

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very… Read More »The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials

  • by

What You Should Know: –BioIntelliSense announced it has entered into a strategic partnership with The Leukemia & Lymphoma Society (LLS) to incorporate the BioSticker™ platform in clinical trials of hematological cancer patients. – The LLS clinical trials will include use of the BioSticker medical device… Read More »BioIntelliSense Partners with Leukemia & Lymphoma Society for Continuous Monitoring in Clinical Trials

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

  • by

Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and… Read More »Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

  • by

With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics… Read More »Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

  • by

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since… Read More »NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

Who Will Be the Next F.D.A. Chief?

  • by

Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

  • by

Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected… Read More »BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

  • by

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by… Read More »Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

  • by

Shots: The companies collaborated to evaluate the use of immunoSEQ T-MAP, for which Adaptive will receive quarterly payments + sequencing and data mapping fees AstraZeneca to provide cancer patients’ biological samples while Adaptive will sequence the samples & deliver TCR-antigen mapping data using its clinical… Read More »AstraZeneca Collaborates with Adaptive on Mapping Immune Response in Cancer

COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021

  • by

What You Should Know: – COVID-19 care deferrals lead to three major boomerang conditions that payers and providers must proactively address in 2021, according to a newly released report by Prealize. – COVID-19’s hidden victims—those who avoided or deferred care during the pandemic—will increasingly return… Read More »COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021

DaVita & RenalytixAI Partner for Early Risk Identification to Help Slow Kidney Disease Progression

  • by

What You Should Know: – RenalytixAI and DaVita announce a program partnership that aims to slow kidney disease progression and improve outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). – This is the first clinical-grade program that delivers advanced early-stage… Read More »DaVita & RenalytixAI Partner for Early Risk Identification to Help Slow Kidney Disease Progression

Arsenic in Infant Rice Cereal

  • by

When it comes to rice and rice-based products, pediatric nutrition authorities have recommended that arsenic intake should be as low as possible. “The US Food and Drug Administration (FDA) has been monitoring the arsenic content in foods” for decades, yet despite the “well-established science describing… Read More »Arsenic in Infant Rice Cereal

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

  • by

Servier Acquires Agios’ Cancer Portfolio in a USD 2 Billion Deal The year is a prime witness of pricey deals and acquisitions in the pharmaceutical industry. To leave its mark, another player decided to hop onto the list. French drugmaker Servier has announced the acquisition… Read More »Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer

  • by

Shots: The recommendation is based on a P-II DESTINY-Breast01 study assessing trastuzumab deruxtecan in patients with HER2 positive unresectable/ m-BC prior treated with trastuzumab emtansine The trial demonstrated a meaningful & durable activity in patients who had received two or more prior anti-HER2 therapies. The… Read More »Daiichi Sankyo and AZ’s Trastuzumab Deruxtecan Receives CHMP’s Recommendation for Approval to Treat HER2 Positive Metastatic Breast Cancer

LeenTaaS Secures $130M for ML Platform to Help Hospitals Achieve Operational Excellence

  • by

What You Should Know: – LeanTaaS raises $130 million in Series D Funding to strengthen its machine learning platform to continue helping hospitals achieve operational excellence during a time where they are facing mounting financial pressures due to COVID-19.  – LeanTaaS provides software solutions that… Read More »LeenTaaS Secures $130M for ML Platform to Help Hospitals Achieve Operational Excellence

Virtual Engagement During COVID Pushes Paradigm Shift for Physician Training and Patient Care

  • by

Shalini Shah, MD is Vice-Chair and Associate Professor, Department of Anesthesiology & Perioperative Care, and Enterprise Director of Pain Services, UC Irvine Health The dominant presence of COVID-19 has not meant the absence of cancer, ear infections, heart attacks, chronic pain, or other illnesses that… Read More »Virtual Engagement During COVID Pushes Paradigm Shift for Physician Training and Patient Care

Why Was Chicken the Primary Source of Arsenic Exposure in Children?

  • by

What was the National Chicken Council’s response to public health authorities calling for the industry to stop feeding arsenic-based drugs to poultry? “Dietary practices influence our exposure to pesticides, toxic heavy metals, persistent organic pollutants, and industrial pollutants….A diet high in fish and other animal products,… Read More »Why Was Chicken the Primary Source of Arsenic Exposure in Children?

Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others

  • by

Neela Montgomery, EVP & President at CVS Pharmacy/Retail CVS Health Corporation names Neela Montgomery Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020. Montgomery will oversee the company’s 10,000 pharmacies across the United States. Montgomery, currently a Board Partner at venture capital… Read More »Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others

Volaris Group Acquires Clinical Workforce & Workflow Platform medaptus

  • by

What You Should Know: – Volaris Group acquires medaptus, a clinical workforce, and workflow solutions that empower healthcare delivery entities to achieve their desired patient, clinical and financial outcomes. Today, Volaris Group has acquired medaptus, a healthcare technology company that removes the administrative burden from… Read More »Volaris Group Acquires Clinical Workforce & Workflow Platform medaptus

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

  • by

CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors… Read More »German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices

  • by

What You Should Know: – RxVantage has acquired onPoint Oncology to provide cancer care teams with on-demand access to educational resources, reimbursement data, and analytics. – The acquisition of onPoint Oncology builds on RxVantage’s rapidly expanding digital offerings for providers. In April, RxVantage launched Virtual Meetings to help providers… Read More »M&A: RxVantage Acquires onPoint Oncology to Expand Offering to Oncology Practices

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

  • by

Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left… Read More »Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

  • by

Shots: The approval is based on a biomarker subgroup analysis of P-III PAOLA-1 study assessing Lynparza + bevacizumab vs bevacizumab alone as 1L maintenance treatment in patients with newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometrioid ovarian, fallopian tube, peritoneal cancer who had CR/PR to… Read More »AstraZeneca and MSD’s Lynparza (olaparib) Receive EU’s Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer

  • by

Shots: The pivotal P-III MONALEESA-7 study assessing Kisqali + endocrine therapy vs PBO + endocrine therapy, in pre- & perimenopausal women with HR+/HER2- advanced or metastatic-BC The study met its 2EPs of OS, demonstrating a significant improvement in OS, and is consistent for the NSAI… Read More »Novartis Reports Results of Kisqali (ribociclib) in P-III MONALEESA-7 Study in Women with HR+/HER2- Advanced Breast Cancer

Jounce shares crash after it abandons immunotherapy combination trial

  • by

Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy will likely fail to produce results in non-small cell lung cancer. Jounce was combining its vopratelimab with BMS’ already-approved Yervoy, hoping that the experimental drug will bolster… Read More »Jounce shares crash after it abandons immunotherapy combination trial

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

  • by

Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing… Read More »AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer

  • by

Shots: The approval is based on PRIMA study assessing Zejula (300mg qd), later amended to incorporate an individualised starting dose of Zejula (200 mg or 300 mg, qd) based on the patient’s baseline weight and/or platelet count Results: The PRIMA study improved PFS for patients… Read More »GSK’s Zejula (niraparib) Receives EC’s Approval as a Treatment in Advanced Ovarian Cancer

FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment

  • by

What You Should Know: – FDA awards AppliedVR Breakthrough Device designation for treating treatment-resistant fibromyalgia and chronic intractable lower back pain – AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive-behavioral therapy (CBT) principles and other behavioral methods. AppliedVR, a pioneer advancing… Read More »FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

  • by

What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the… Read More »JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

  • by

Shots: AstraZeneca’s Tagrisso has received sNDA’s acceptance and has been granted PR in the US for the adjuvant treatment of patients with early-stage (IB, II, and IIIA) EGFRm NSCLC after complete tumor resection with curative intent The sNDA is based on the P-III ADAURA trial… Read More »AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer

Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density

  • by

What You Should Know: – FUJIFILM Medical Systems U.S.A., Inc. and Volpara Solutions announced the extension of their partnership to provide mammography facilities and clinicians with breast imaging solutions designed to improve image quality, streamline workflow and accurately assess a patient’s breast density. – Building… Read More »Fujifilm & Volpara Partner to Help Clinicians Determine Patient Breast Density

AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

  • by

What You Should Know: – Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression. – In work funded through the PHDA-AWS collaboration, a research team led by… Read More »AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease

  • by

The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers. In August the FDA’s Oncology Drugs Advisory Committee voted nine to one in favour of approving Ryoncil (remestemcel-L), making… Read More »Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease

Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video

  • by

US representative Katie Porter used her now-signature whiteboard as she questioned former Celgene CEO Mark Alles over the connection between the significant price hike for Revlimid, a common cancer drug, and his personal bonus. The Democratic congresswoman for California presented her argument during a House oversight and… Read More »Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video

TIGIT Therapies Digital Summit

  • by

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical… Read More »TIGIT Therapies Digital Summit

NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

  • by

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection. The new guidance recommends Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine, for adults with diffuse large B-cell lymphoma (DLBCL), in second line… Read More »NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

  • by

What You Should Know: The FDA and Syapse announce research collaboration expansion to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19. As part of the research, Syapse is partnering with FDA’s Oncology Center of Excellence to investigate methods to… Read More »FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

GSK nabs FDA approval for first-in-class multiple myeloma drug

  • by

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.

Armpit Shaving and Breast Cancer

  • by

Shaving before applying underarm antiperspirants can increase aluminum absorption. Could this explain the greater number of tumors and the disproportionate incidence of breast cancer in the upper outer quadrant of the breast near the armpit? A famous case report called “The Mortician’s Mystery,” published in… Read More »Armpit Shaving and Breast Cancer

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

  • by

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of… Read More »Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Bacteria and Colon Cancer

  • by

Let’s catch on some non-coronavirus research today with an interesting approach against a very bad disease, metastatic colon cancer. This new paper (from groups at Virginia Tech and Wake Forest) adds to our understanding of something that’s been noticed for some time: colon cancer tissue… Read More »Bacteria and Colon Cancer

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

  • by

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic… Read More »Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

Virtually or In-Person, Automation Improves The Healthcare Experience

  • by

Muthu Alagappan, MD, Medical Director at Notable Health The COVID-19 pandemic has caused an unprecedented shift in the way consumers view and access a variety of goods and services—and healthcare is no exception. Recent studies show that many patients, including vulnerable populations like those living with cancer, are delaying recommended care and… Read More »Virtually or In-Person, Automation Improves The Healthcare Experience

Merck KGaA takes second option from cancer immunotherapy pact with F-Star

  • by

Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics.  The companies signed a deal to develop cancer immunotherapies in summer 2017, where Darmstadt-based Merck KGaA paid $115 million up front, agreeing to further payments during the first two years of… Read More »Merck KGaA takes second option from cancer immunotherapy pact with F-Star

NICE backs NHS use for Astellas’ Xospata after rethink

  • by

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia.  In final draft guidance NICE said that the drug is recommended for relapse or refractory FLT3 mutation-positive AML, giving patients an alternative to chemotherapy and its unpleasant side effects.  However because of… Read More »NICE backs NHS use for Astellas’ Xospata after rethink

Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize

  • by

Cumberlege report is a damning reminder of how arrogant, intimidating doctors have suppressed their patients’ views Julia Cumberlege’s report into avoidable harm inflicted by the healthcare system exposes an institutional inability to listen to patients in general and women in particular. Her investigation into decades… Read More »Pelvic mesh scandal is what happens when men with power ignore women | Richard Vize

Philips and BioIntelliSense Integrate to Enhance Remote Patient Monitoring

What You Should Know: – Philips integrates the BioIntelliSense FDA-cleared BioSticker™ sensor as part of its remote patient monitoring solutions for patients outside the hospital. – Multi-parameter sensors aid monitoring across multiple chronic conditions with medical-grade vital signs for physicians to remotely track core symptoms,… Read More »Philips and BioIntelliSense Integrate to Enhance Remote Patient Monitoring

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

  • by

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5… Read More »Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

  • by

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

Chia Seeds vs. Flaxseeds

  • by

  What effect do chia seeds have on weight loss, blood sugar, cholesterol, blood pressure, and inflammation? We’ve been eating chia seeds for more than 5,000 years. Historically, they are one of the main crops grown in the Western hemisphere. They are exceptionally high in… Read More »Chia Seeds vs. Flaxseeds

Medical Meat Bias

When famed surgeon Michael DeBakey was asked why his studies published back in the 1930s linking smoking and lung cancer were ignored, he had to remind people about what it was like back then. We were a smoking society. Smoking was in the movies, on… Read More »Medical Meat Bias